Table 2.
Sleep architecture in subgroup of participants (n = 11)
| Before substance administration: Sleep onset to 3:55 A.M. |
After substance administration: 4:05 to 6:45 A.M. |
|||||||
|---|---|---|---|---|---|---|---|---|
| Placebo | Metyrapone | t (10) | p | Placebo | Metyrapone | t (10) | p | |
| TSP (min) | 271.63 ± 19 | 269.45 ± 31 | 0.216 | 0.834 | 143.31 ± 15 | 147.18 ± 4 | 0.758 | 0.466 |
| TST (min) | 262.5 ± 20 | 258.18 ± 24 | 0.486 | 0.638 | 135.36 ± 19 | 120.54 ± 12 | 1.976 | 0.076 |
| N1%TSP | 2.24 ± 1.29 | 3.16 ± 2.01 | 1.370 | 0.201 | 7.71 ± 6.71 | 29.52 ± 18.77 | 4.593 | 0.001 |
| N2%TSP | 37.38 ± 9.44 | 39.23 ± 6.82 | 0.732 | 0.481 | 41.14 ± 11.98 | 40.08 ± 18.71 | 0.170 | 0.868 |
| N3%TSP | 38.87 ± 8.16 | 38.48 ± 6.73 | 0.128 | 0.900 | 12.95 ± 10.21 | 0.13 ± 0.43 | 4.238 | 0.002 |
| REM %TSP | 18.11 ± 5.61 | 15.16 ± 4.05 | 1.471 | 0.172 | 32.44 ± 9.58 | 12.14 ± 7.83 | 4.630 | 0.001 |
TSP: total sleep period; TST: total sleep time; N1: NREM sleep stage 1; N2: NREM sleep stage 2; N3: NREM sleep stage 3; REM: rapid eye movement sleep stage. Statistically significant differences between conditions are depicted in bold.